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There is a great need for the development of therapeutic strategies that can target biomolecules to damaged
myocardium. Necrosis of myocardium during amyocardial infarction (MI) is characterized by extracellular
release of DNA, which can serve as a potential target for ischemic tissue. Hoechst, a histological stain that
binds to double-stranded DNA can be conjugated to a variety of molecules. Insulin-like growth factor-1
(IGF-1), a small protein/polypeptide with a short circulating-half life is cardioprotective followingMI but its
clinical use is limited by poor delivery, as intra-myocardial injections have poor retention and chronic
systemic presence has adverse side effects. Here, we present a novel delivery vehicle for IGF-1, via its
conjugation to Hoechst for targeting infarcted tissue. Using a mouse model of ischemia-reperfusion, we
demonstrate that intravenous delivery of Hoechst-IGF-1 results in activation of Akt, a downstream target of
IGF-1 and protects from cardiac fibrosis and dysfunction following MI.
D
espite significant advances in therapy, a substantial proportion of patients treated for myocardial infarc-
tion (MI) develop congestive heart failure1. Recent breakthroughs in regenerative medicine with cell and
growth factor based therapies show tremendous potential in reducing this risk. Current pharmacologic
and device therapies however do not target damagedmyocardium or recover functional myocardium, and rather
serve to boost cardiac function and reduce inflammation. As damage from MI is mainly regional, localized
therapy holds the most promise2.
Growth factor based therapeutics have shown great potential in regenerating the heart3. Insulin-like growth
factor-1 (IGF-1) has demonstrated a cardio-protective and regenerative effect on the myocardium4. These
benefits are primarily ascribed to the short-term actions of IGF-1 via activation of pro-survival pathways such
as those mediated via Akt. In contrast, chronic exposure may be deleterious, associated with the development of
pathologic cardiac hypertrophy and cancer5,6. Regulating the temporal effects of IGF-1 has been challenging, in
part by its short circulating half-life, which has required prolonged infusions of growth hormone to raise IGF-1
levels, and its small size (,9 kDa), which results in poor tissue retention following direct injection7. For example,
direct delivery of free IGF-1 to the infarcted heart does not allow for sufficient retention and does not lead to any
improvement in cardiac function7. Thus, finding new ways to acutely localize IGF-1 delivery to the damaged
myocardium could maximize its therapeutic benefits.
During an acuteMI, excessive necrosis releases DNA in to the extracellular space. Given that nearly tenmillion
cells show compromised cell membranes in rat models of MI8 this could mean on the order of picograms of DNA
per cardiac cell. With estimates that scale rat to human studies demonstrating billions of myocytes potentially
undergoing necrosis following acute MI, this represents a significant clinical target. In fact, high levels of
circulating cell-free DNA have been found to correlate with myocardial necrosis in patients suffering from
MI9 and other cardiovascular diseases such as peripheral artery disease, indicating other potential indications
for using a DNA-targeting approach.
In this study, we demonstrate that IGF-1 conjugated to a DNA binding agent through streptavidin-biotin
linkages can bind extracellular DNA and improve IGF-1 retention at sites of myocardial injury following MI.
DNA binding dyes, such as Hoechst, have a high affinity for DNA (,60 nM)10 thus allowing them to localize to
damagedmyocardium by bindingDNA released fromdying cells. In addition, Hoechst has a history of being used
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therefore hypothesized that IGF-1 conjugation to Hoechst would
allow IGF-1 to be delivered to areas of myocardial injury and attenu-
ate MI-induced cardiac dysfunction and fibrosis.
Results
Creation and in-vitro validation of Hoechst-IGF-1. To conjugate
IGF-1 to Hoechst, we used Hoechst previously modified by the
addition of poly(ethylene glycol) (PEG) with a functional amine
group13 and further functionalized by the addition of a biotin
moiety (Figure 1a). The structure of the final compound was
verified through 1H-Nuclear magnetic resonance (Supplemental
Fig. 1). Using biotin-streptavidin binding, biotinylated-human
IGF-1 was then tethered to Hoechst-PEG-biotin to create Hoechst-
IGF1 (H-IGF1), or attached to free biotin to make streptavidin-IGF1
(S-IGF1) as a non-targeted control (Figure 1b). Since each mole of
streptavidin has 4 available binding sites for biotin, we expected
Hoechst and IGF-1 to bind streptavidin in a 25251 molar ratio
with the molecular weight of the final complex to be between 70
and 80 kDa. To confirm the size of the H-IGF1 complex and the
presence of IGF-1, we immunoblotted against IGF-1. Two distinct
Figure 1 | Hoechst-IGF1 synthesis and bioactivity. (A) Hoechst-amine was functionalized by the addition of a PEG-Biotin to allow for conjugation with
IGF-1. (B) Using the biotin-streptavidin interaction, Hoechst-biotin was incubated with biotinylated-IGF-1 and tetravalent streptavidin to create the
Hoechst-IGF1 (H-IGF1) complex. A control compound, streptavidin-IGF1 (S-IGF1) containing only streptavidin, biotin and biotinylated-IGF-1 was
also assembled. (C) Immunoblot for IGF-1 demonstrating the size of H-IGF1 species at 70 and 80 kDa (right lane) compared to biotinylated-IGF-1 at
10 kDa (left lane). (D) Live and methanol fixed RAW 264.7 macrophages were treated with H-IGF1 or Hoechst-biotin for 15 minutes. Hoechst
compounds remained membrane impermeable to live cells as demonstrated by low levels of blue fluorescence. In contrast, permeabilized cells had high
levels of blue, nuclear fluorescence demonstrating the DNA binding capability of Hoechst. White scale bar represents 100 mm. (E) Cardiomyoblasts
(H9c2 cells) were treated with control media, streptavidin, IGF-1, biotinylated-IGF-1 or H-IGF1 for 15 minutes. Cells were homogenized and
immunoblotted for Akt phosphorylation. H-IGF1 treatment activated Akt to a similar extent as IGF-1 and biotinylated-IGF-1.
www.nature.com/scientificreports
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bands for H-IGF1 were observed between 70 and 80 kDa, likely
reflecting the different binding ratios of IGF-1 and Hoechst to
streptavidin. As expected, biotin-IGF-1 was observed at 10 kDa
(Figure 1c).
An important consideration in localizing H-IGF1 to areas of myo-
cardial damage is the selective targeting of DNA that is extracellular
and ensuring that the H-IGF1 complex remains cell impermeable.
We had previously shown that PEGylation and functionalization of
the imaging agent, Hoechst-IR conferred membrane impermeab-
ility13. To test if H-IGF1 behaved similarly, live and methanol fixed
RAW 264.7 macrophages were incubated with H-IGF1 and imaged
by fluorescence microscopy (Figure 1d). Treatment of live cells with
either Hoechst-biotin or H-IGF1 demonstrated little to no nuclear
fluorescence, indicating lack of cell permeability. In contrast, meth-
anol-treated, permeabilized cells incubated with Hoechst-biotin or
H-IGF1 generated high levels of intracellular fluorescence confirm-
ing that low intracellular fluorescence was due to the membrane
impermeability of H-IGF1 and not due to a reduction in its DNA
binding capability. Additionally, this also served to demonstrate that
the functionalized Hoechst compounds could still bind DNA. Next,
we confirmed the bioactivity of H-IGF1. Cardiomyoblasts (H9c2
cells) were quiesced in serum free media, washed and treated with
controlmedia, streptavidin or 50 ng/ml of IGF-1, biotinylated-IGF-1
orH-IGF1 for 15minutes. As seen in the representative immunoblot,
H-IGF1 phosphorylated Akt to a similar extent as both IGF-1 and
biotinylated-IGF-1 (Figure 1e). These data demonstrate that both
Hoechst and IGF-1 remain bioactive when conjugated to one
another.
Intravenous administration of Hoechst-IGF-1 selectively binds
exposed DNA and targets injured myocardium. To determine if
Hoechst binds to DNA in areas of myocardial damage in vivo, we
injected 500 mg of Hoechst-biotin intravenously into rats subjected
to ischemia-reperfusion (IR) or sham surgery. Confocalmicrographs
from hearts from sham animals demonstrated intact cell membranes
in the left ventricle (LV) withminimal DNA binding, as evidenced by
low levels of blue fluorescence. In contrast, IR hearts showed loss of
membrane integrity with diffuse interstitial blue staining, indicating
increased DNA binding (Figure 2a). Of note was the lack of any
nuclear staining of Hoechst in sham or MI animals, indicating it
did not enter intact, healthy cells. While rats were used to generate
clear, morphologically distinguishable sections, all subsequent
studies used mice.
DNA release from necrotic cells following MI typically occurs at
1–2 hours, peaks at 9–18 hours and disappears by 72 to 96 hours14. In
order to ensure that an adequate amount of extracellular DNA was
available to bind Hoechst, we subjected mice to 30 minutes of ische-
mia followed by reperfusion (IR) by ligating the left anterior descend-
ing artery and allowed 6 hours for sufficient necrosis to develop.Mice
were then injected intravenously (tail vein) with either 110 mL of PBS
or equivolume amounts of S-IGF1 or H-IGF1 containing 200 ng of
IGF-1. At 2, 18 and 48 hours following injection, mice were sacrificed
and organs harvested for imaging using a fluorescence imaging sys-
tem (Figure 2b). The streptavidin linker used to createH-IGF1 and S-
IGF1 compounds contained a fluorophore, which was detected using
a Cy5.5 filter. Fluorescence was then quantified to determine IGF-1
levels by plotting fluorescence intensity on standard curves generated
by known amounts of IGF-1, as determined by ELISA (Supplemental
Fig. 2). We specifically measured fluorescence in the LV, the major
site of ischemic injury and DNA extrusion. Two hours following
injection, there was an increase in fluorescence in the LV of both
S-IGF1 and H-IGF1 treated animals, with no difference in IGF-1
levels between the two groups. This initial increase in IGF-1 levels
likely resulted from passive accumulation of both H-IGF1 and S-
IGF1 due to enhanced permeability of the vasculature, a well-
described phenomenon that typically occurs after ischemic injury15.
By 18 hours, LV IGF-1 levels fromH-IGF1 treated mice increased by
27%, accumulating 21.8% of injected dose per gram of tissue, second
only to the liver. In contrast, LV IGF-1 levels from S-IGF1 treated
mice decreased to 11.9%ID/g tissue, accumulating significantly less
IGF-1 than the liver, spleen and lung (Figure 2c). IGF-1 levels in the
liver, spleen, muscle and kidney were not statistically different
between H-IGF1 and S-IGF1 treated mice. At 48 hours, IGF-1 levels
in the LV from H-IGF1 treated mice began trending down but
remained significantly greater than S-IGF1 treated mice.
Additionally, no H-IGF1 was detected in blood samples at any of
the 3 time points.
Many of the cardio-protective actions of IGF-1 are exerted via
Akt7. We therefore measured the phosphorylation of Akt at the same
time points used to determine IGF-1 targeting. In preliminary stud-
ies, we measured no significant changes over time in Akt phosphor-
ylation in vehicle treatedmice (Supplemental Figure 3). Similar to the
temporal accumulation of IGF-1 in the LV, we found significantly
greater phosphorylation of Akt in H-IGF1 mice over control but not
S-IGF1mice at 2 hours. However, by 18 hours, Akt activation peaked
and was significantly greater in the LV of H-IGF1 treated mice than
S-IGF1mice. By 48 hours, Akt activation inH-IGF1 treatedmice was
reduced and was similar to levels seen in S-IGF1 treated mice
(Figure 2d). Sham animals were used a control (dotted lines) to
determine relative levels of increase. These data demonstrate that
IGF-1 accumulation and activation of its downstream target occur
in a time-dependent manner and parallel the accumulation of DNA
into the extracellular space. To determine specificity for DNA, H-
IGF-1 was preincubated with excess double-stranded DNA (10003)
prior to injection and imaging performed at 30 minutes. There was a
significant decrease in localized H-IGF-1 that was preincubated with
DNA as compared to H-IGF1 alone (Figure 2e).
Hoechst-IGF-1 administration in-vivo preserves cardiac function
and prevents cardiac fibrosis following ischemia-reperfusion. In
addition to determining IGF-1 targeting and retention in the LV, we
also measured its functional impact. Cardiac function was assessed
by echocardiography at 14 and 28 days following IR surgery and by
invasive hemodynamics at 28 days. At both 14 (Supplemental Fig. 4)
and 28 days, fractional shortening was greater in S-IGF1 andH-IGF1
treated mice compared to IR mice injected with vehicle. H-IGF1
treated mice however, demonstrated significantly greater cardiac
contractility than S-IGF1 treated mice (Figure 3a). Moreover, H-
IGF1 treatment was associated with improved ejection fraction
(Figure 3b), end-systolic (Figure 3c) and end-diastolic volumes
(Figure 3d) as measured by invasive pressure-volume measure-
ments. Given the improvement in cardiac remodeling with H-
IGF1 treatment, we hypothesized that increased IGF-1 delivery to
the heart limited the development of cardiac fibrosis and reduced
cardiac dysfunction. Histologic sections from 28 day-old mice were
stained for collagen with Picrosirius red. Similar to the improvement
in fractional shortening, both S-IGF1 and H-IGF1 treatments were
associated with less cardiac fibrosis compared to control hearts, with
H-IGF1 treated mice demonstrating markedly less cardiac fibrosis
than S-IGF1 treated mice (Figure 3e).
Discussion
The ability to harness the promising potential of growth-factor-
based therapy has been hampered by ineffective and potentially
harmful delivery methods. In this report, we demonstrate for the
first time that extracellular DNA released from necrotic cell death
can be used as a target to deliver hormone therapy such as IGF-1.We
show that a single intravenous injection of IGF-1 tethered toHoechst
results in increased IGF-1 localization to areas of cardiac injury with
subsequent activation of Akt, through which many of its anti-apop-
totic and cell proliferative effects occur. Whether this increase in
IGF-1 accumulation results from greater Hoechst-mediated IGF-1
www.nature.com/scientificreports
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delivery and subsequent DNA binding or is a consequence of
reduced clearance of the Hoechst-DNA complex is unclear.
Moreover, steric hindrance from the PEG-Hoechst chain could
impede nucleases that normally degrade exposed DNA and contrib-
ute to increased retention of IGF-1 in the necrotic tissue. Finally, the
addition of streptavidin (and PEGylated Hoechst) to IGF-1 may
block the binding of IGF-1 binding proteins that are responsible
for sequestering IGF-1 from the circulation. Despite these uncertain-
ties, it is clear from the data that delivery of a growth factor with poor
pharmacokinetics based on enhanced permeability is not effective.
We elected to use streptavidin-biotin chemistry to link Hoechst to












































































Figure 2 | Hoechst increases IGF-1 localization to infarcted myocardium. (A) Rats were subjected to ischemia-reperfusion (IR) surgery. One day later
Hoechst-biotin was injected and allowed to circulate for 1 h. Frozen sections were made and tissue was examined via red autofluorescence of the
myocardium. Sham operated animals showed cell membrane integrity in the left ventricle (LV) and little blue fluorescence. IR-operated animals showed
necrosis in the LV and diffuse blue staining suggesting release of DNA (Scale bar 5 200 mm). (B) Imaging of hearts harvested frommice at the indicated
time-point. Hoechst increased IGF-1 accumulation at 18 hours compared to S-IGF1 (n 5 4–7 per group; * p, 0.05 vs. S-IGF1, ** p, 0.01 vs. SIGF1,
two-way ANOVA followed by Bonferroni post-test). (C) Imaging was used to quantify IGF-1 as %ID per gram of tissue at 18 h.While other organs were
similar, there was a significant increase in the heart of H-IGF1 treated mice compared to S-IGF1 treatment (n $ 5 per group, *p , 0.05; t-test). (D)
Western blots showing phosphorylation of Akt in the LV of mice treated with S-IGF1 or H-IGF1. By 18 hours, Akt phosphorylation in H-IGF1 treated
mice was significantly greater than S-IGF1 treated mice. Line represents PBS treated IRmice. (* p, 0.05 vs. S-IGF1 at 18 hours, n 5 3–7 per group, two-
way ANOVA followed by Bonferroni post-test). (E) Mice were treated with S-IGF1, H-IGF1, or H-IGF1 pre-incubated with 10003 excess of double-
stranded DNA. Pre-incubation with DNA significantly decreased IGF-1 levels. (*p, 0.05 vs. S-IGF1, # p, 0.05 vs. H-IGF1, n5 5–7 per group, one-way
ANOVA followed by Bonferroni post-test).
www.nature.com/scientificreports
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modify IGF-1, as well as the fact that our other Hoechst-reactive
agents were primarily sulfhydryl-reactive7,13. IGF-1 has several
cysteines that all are involved in complex disulfide bond formation
which limits their use as reactive groups. Additionally, adding extra
cysteines could interfere with protein folding and was not used. It is
also likely that we had a heterogeneous mixture of species within our
final formulation.While ourWestern blot data demonstrated a range
of 1–2 IGF molecules per streptavidin, we were unable to determine
howmanyHoechstmolecules there were permolecule of compound.
Thus, due to incomplete binding or other reasons, there may have
Figure 3 | Hoechst-IGF1 preserves cardiac function and attenuates cardiac fibrosis following MI. (A) Representative echocardiographic M-mode
images and bar graph depicting cardiac contractility at 28 days following IR. As shown, H-IGF1 treated mice demonstrated greater percent fractional
shortening than PBS and S-IGF1 treatedmice (%FS, mean6 SEM: 41.556 2.49 vs. 29.186 3.51 vs. 27.836 1.06). * p, 0.01 vs. S-IGF1, ** p, 0.001 vs.
PBS, n 5 5–9 per group, one-way ANOVA followed by Tukey’s post-test. (B–D) Invasive cardiac hemodynamic measurements determined at 28 days
following IR. H-IGF1 treatment led to significantly improved (B) Ejection fraction and (C) End-diastolic volumes compared to PBS and S-IGF1 treated
mice. (D) End-systolic volumes were not different between sham and H-IGF1 treated mice (n 5 5 per group, *p, 0.05 vs. sham mice, # p, 0.05 vs. S-
IGF1 treated mice, one-way ANOVA followed by Tukey’s post-test). (E) Representative Picrosirius red images from histologic sections of hearts from
PBS, S-IGF1 andH-IGF1 treatedmice. Black scale bar represents 1 mm.H-IGF1 treatment reduced collagen content in the left ventricle compared to PBS
treated mice (n 5 5–6 per group, *, p , 0.05 vs. PBS, one-way ANOVA followed by Tukey’s post-test).
www.nature.com/scientificreports
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been some streptavidin molecules with 1 IGF molecule bound and a
range of 1–3 Hoechst molecules (as streptavidin has 4 biotin binding
sites). Additionally, while we dialyzed over several hours with large
volumes of buffer, it is possible that not all unbound Hoechst-biotin
was removed. While the affinity of biotin for streptavidin is high and
we believe there were likely not many free Hoechst-biotin molecules,
we cannot rule this out and it may compete with the H-IGF1 for
DNA.
Our data is also consistent with previous reports of cardioprotec-
tion from IGF-1 therapy16,17. These beneficial effects have been attrib-
uted to Akt induced myocyte survival through an anti-apoptotic
effect18, angiogenesis19 and the protection of resident progenitor stem
cells in the heart20. These data indicate that a single, systemic injec-
tion of H-IGF1 is able to preserve cardiac function and limit the
development of cardiac fibrosis following MI. Moreover, we wish
to point out that only 200 ng of IGF-1 were injected, reducing the
possibility for toxic effects seen at larger, prolonged doses5,6.With the
broad chemistry surrounding functionalized PEG used to create
Hoechst derivatives, it may be possible to target other therapies such
as cells, small molecules, and even nanoparticles. We believe that the
use of DNA binding agents such as Hoechst can be used to target
exposed DNA in other diseases where necrotic cell death plays a
critical role and could be used as a platform therapy.
Methods
Synthesis of hoechst compounds. Hoechst-amine was synthesized as previously
described13. Hoechst-biotin was synthesized from Hoechst-amine using NHS/EDC-
coupling chemistry. EZ-link NHS-PEG12-Biotin was purchased from Thermo/
Pierce. Twenty-five milligrams of Hoechst-amine was dissolved in 5 ml of anhydrous
dimethyl formamide (DMF) with 20 equivalents of triethylamine under nitrogen).
One equivalent of NHS-PEG compound was added to the reaction mixture and
stirred overnight. Progress was monitored using TLC (MeOH:DCM). Upon
completion of the reaction, DMF was removed under reduced pressure and the
reaction mixture dissolved in 20% methanol (MeOH) in DCM with 0.5%
triethylamine. This mixture was streaked on preparative TLC plates and developed
using 10%MeOH in DCMwith 0.5% triethylamine. The product band was identified
using a UV lamp and scraped off and MeOH:DCM used to extract the product.
H-IGF1was then generated using biotin-streptavidin chemistry. Since Streptavidin
has 4 potential binding sites, Hoechst-biotin, human biotinylated-IGF-1 (immuno-
logical and biochemical test systems) and Streptavidin (labeled with a fluorescent tag,
Thermo-Scientific Dylight 650) were combined in a 25251 molar ratio for 3 hours at
37uC in PBS. The resulting mixture was dialyzed against PBS (10003) for 3 hours (3
changes, 1 hour each) to remove any unbound biotinylated-IGF-1 and Hoechst-
biotin. The remaining sample was then extracted from the dialysis chamber and
stored in 220 C. The final concentration of IGF-1 of H-IGF1 and S-IGF1 conjugates
was measured using a human-specific IGF-1 ELISA kit (VWR) as per manufacturers’
instructions.
RAW 264.7 cells. RAW 264.7 macrophages were incubated with either Hoechst-
Biotin or H-IGF1 (20 mM) in DMEM containing 10% serum for 30 minutes at 37uC.
The cell media was then replaced by warm Krebs-Ringer buffer and the cellular
fluorescence was recorded using a fluorescence microscope (Nikon E600, Nikon,
Melville, NY), using an excitation wavelength of 340 nm and an emission filter
between 400–500 nm. In case of fixed cells, RAW264.7macrophage cells were treated
with pre-cooled methanol at 220 C for 10 minutes. The cells were washed with PBS
followed by incubation with H-IGF1 for 30 min at 37 C. The cell media was then
replaced by Krebs-Ringer buffer and the cellular fluorescence was recorded using a
fluorescence microscope, with an excitation wavelength of 340 nm and an emission
filter between 400–500 nm.
Cardiomyoblast culture.H9c2 cells were purchased from ATCC and were plated at
confluence 24 h before experiments in Dulbecco’s Modified Eagle Medium
containing l-glutamine, penicillin/streptomycin, and 2% fetal bovine serum. Media
was then aspirated and replaced with treatment media (serum-free) containing either
50 ng/mL of IGF-1, B-IGF1, H-IGF1, Streptavidin or equal volume of PBS. After 15
minutes, media was aspirated and cells homogenized for protein extraction.
Myocardial infarction. Adult male mice 8 to 12 weeks old, fed an alfalfa-free diet
were subjected to myocardial infarctions (MI) by ischemia-reperfusion (IR) surgery
in a randomized and double-blind manner. Briefly, the animals were anaesthetized
(1–3% isoflurane, Webster Veterinary) and, following tracheal intubation, hearts
were exposed by separation of the ribs. Myocardial infarction was induced by ligation
of the left anterior descending coronary artery with a suture for a period of 30
minutes. The suture was then released and the heart reperfused. The chest was closed
and the animals allowed to recover for 6 h to generate sufficient myocardial necrosis.
After 6 hours, 110 ul of PBS, S-IGF1 or H-IGF1 were administered to mice via tail
vein injection. Both S-IGF1 and H-IGF1 treatments were prepared in PBS and
contained 200 ng of human-IGF-1 at 2, 18 and 48 hours, hearts were extracted,
perfused with PBS and imaged directly under a fluorescence microscope (Xenogen
IVIS 200 camera). All studies were performed in a randomized and blinded manner
and were approved by the Emory University Institutional Animal Care and Use
Committee.
Fluorescence imaging. In vivo fluorescence imaging was performed with an IVIS 200
small animal imaging system (Xenogen, Alameda, CA). A Cy5.5 filter set was used for
acquiring H-IGF1 and S-IGF1 fluorescence in vivo. Identical illumination settings
(lamp voltage, filters, f/stop, field of views, binning) were used for acquiring all
images, and fluorescence emission was normalized to total efficiency. Images were
acquired and analyzed using Living Image 2.5 software (Xenogen, Alameda, CA).
Echocardiography. Two-dimensional echocardiography was performed using a
high-resolution imaging system with a 30-MHz imaging transducer (Vevo 770;
VisualSonics) as described previously21 in anesthetized mice. Briefly the mice were
anesthetized with 1.5–2% isoflurane and thereafter maintained on 1–1.5% isoflurane
throughout the procedure. Two-dimensional echocardiographic images were
obtained and recorded in a digital format. A researcher blinded to the murine
treatment group analyzed images off-line. Left ventricular end-diastolic dimension
(LVDd) and left ventricular end-systolic dimension (LVDs) were measured. Percent
fractional shortening (%FS), which quantifies contraction of the ventricular wall and
is an indication of muscle function, was calculated as % FS 5 ([LVDd 2 LVDs]/
LVDd) 3 100.
Invasive hemodynamic measurements. Briefly, cardiac function was first assessed
under anesthesia by small animal echocardiography (Vevo770R, Visualsonics). Short
axis values of left ventricular end systolic (ES) and end diastolic (ED) dimensions were
obtained and used for pressure-volume calculations. For invasive ventricular function
measurements, animals were anesthetized with isoflurane and placed on a heating
pad. The chest was opened and a 1-French conductance catheter (Millar Instruments,
MPVS Ultra and SPR-838) was introduced apically into the left ventricle. Pressure-
volume loops were acquired with a PowerLab data acquisition system and analyzed
using the LabChart software package (Millar). Catheter was calibrated according to
manufacturer’s instructions. At the completion of the experiment, animals were
euthanized and hearts were excised for fixation and embedding.
Collagen staining. Collagen deposition was determined by Picrosirius red (Sigma)
staining, as previously described22. Briefly, 5-mm tissue sections were stained with
Picrosirius red and imaged using a light microscope. A researcher blinded to
treatment measured total collagen area (red staining) and normalized to total LV area
in 3 separate sections per animal using ImageJ (NIH website).
Western analysis. Total protein was extracted from frozen hearts as described23.
Proteins were resolved by SDS-PAGE and electro-transferred onto a PVDF
membrane (Millipore Corp., Bedford, MA). The following antibodies were used:
phospho-Akt (Ser473), (Cell Signaling Technology, Danvers, MA), Protein detection
was carried out with the appropriate horseradish peroxidase-conjugated secondary
antibody and ECL Plus detection systems (Amersham Biosciences, Piscataway, N.J.).
Densitometry of bands was quantified using ImageJ (NIH Website).
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